Aldeyra Therapeutics (ALDX) Misses Q2 EPS by 3c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q2 EPS of ($0.46), $0.03 worse than the analyst estimate of ($0.43).

"As our lead product candidate reproxalap has advanced to four late-stage clinical programs, our development pipeline continues to grow, and now features a number of novel compounds across multiple diseases and mechanisms of action," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "We look forward to announcing Phase 2b clinical results in dry eye disease late third quarter or early fourth quarter this year, Phase 3 clinical results in allergic conjunctivitis late this year or early next year, Phase 3 Part 1 clinical results in Sjögren-Larsson Syndrome next year, and Phase 3 results in noninfectious anterior uveitis next year. Additionally, in September, we expect to announce clinical results from an investigator-sponsored clinical trial with ADX-1612 in malignant mesothelioma."

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cal-Maine Foods adds two independent directors, expanding board to ten
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity